Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome

Ożegowska,Katarzyna; Bogacz,Anna; Bartkowiak‑Wieczorek,Joanna; Seremak‑Mrozikiewicz,Agnieszka; Pawelczyk,Leszek

doi:10.3892/mmr.2016.5910

Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome

Authors:
- Katarzyna Ożegowska
- Anna Bogacz
- Joanna Bartkowiak‑Wieczorek
- Agnieszka Seremak‑Mrozikiewicz
- Leszek Pawelczyk
View Affiliations

Affiliations: Department of Infertility and Reproductive Endocrinology, Poznań University of Medical Sciences, 60‑535 Poznań, Poland, Department of Pharmacology and Phytochemistry, Institute of Natural Fibers and Medicinal Plants, 61‑707 Poznań, Poland, Laboratory of Molecular Biology, Division of Perinatology and Women's Diseases, Poznań University of Medical Sciences, 60‑535 Poznań, Poland
Published online on: October 31, 2016 https://doi.org/10.3892/mmr.2016.5910
Pages: 5401-5407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. A number of PCOS complications may be associated with the elevated level of angiotensin II and low bradykinin concentrations. The aim of the present study was to investigate the frequencies of angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphisms in women with PCOS and to determine the association between ACE genetic variants and the risk of metabolic and cardiovascular complications in such women. A total of 138 PCOS patients and 110 healthy volunteers were enrolled. Cardiovascular risk was estimated according to the criteria of the American Heart Association and Androgen Excess and PCOS Society. The median average age was 28.5 (26.0‑31.0) and 27.0 (24.0‑30.0) years in the control and PCOS groups, respectively (P=0.004). Anthropometric parameters, including body mass index and waist circumference were significantly higher in the PCOS patients. In the PCOS group, 97 (57.4%) of the subjects were metabolically unhealthy, whereas, in the control group 51 (46.4%) subjects were (P=0.07). The II, ID, and DD genotypes frequencies were 29.1, 44.5, and 26.4% in the controls and 5.0, 37.7, and 57.3% in the PCOS patients. The cardioprotective I allele was observed significantly less frequently in the women with PCOS compared with the controls [odds ratio (OR), 3.27; P=0.0001]. The DD genotype, which is known to increase cardiovascular risk, was more frequently observed in PCOS patients (OR, 3.87; P=0.0003), whereas the cardioprotective II genotype occurred in this group less frequently (OR, 0.4; P=0.06). The results of the present study demonstrated a statistically significant association between the ACE I/D polymorphism and the presence and intensity of metabolic disturbances in women with PCOS.

View Figures

View References

1	Yoshimura Y: The ovarian renin-angiotensin system in reproductive physiology. Front Neuroendocrinol. 18:247–291. 1997. View Article : Google Scholar : PubMed/NCBI
2	Van Sande ME, Scharpé SL, Neels HM and Van Camp KO: Distribution of angiotensin converting enzyme in human tissues. Clin Chim Acta. 147:255–260. 1985. View Article : Google Scholar : PubMed/NCBI
3	Soubrier F, Wei L, Hubert C, Clauser E, Alhenc-Gelas F and Corvol P: Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications. J Hypertens. 11:599–604. 1993. View Article : Google Scholar : PubMed/NCBI
4	Palumbo A, Pourmotabbed G, Carcangiu ML, Andrade-Gordon P, Roa L, DeCherney A and Naftolin F: Immunohistochemical localization of renin and angiotensin in the ovary: Comparison between normal women and patients with histologically proven polycystic ovarian disease. Fertil Steril. 60:280–284. 1993. View Article : Google Scholar : PubMed/NCBI
5	Johnson MC, Vega M, Vantman D, Troncoso JL and Devoto L: Regulatory role of angiotensin II on progesterone production by cultured human granulosa cells. Expression of angiotensin II type-2 receptor. Mol Hum Reprod. 3:663–668. 1997. View Article : Google Scholar : PubMed/NCBI
6	Plendl J, Neumüller C, Vollmar A, Auerbach R and Sinowatz F: Isolation and characterization of endothelial cells from different organs of fetal pigs. Anat Embryol (Berl). 194:445–456. 1996. View Article : Google Scholar : PubMed/NCBI
7	Acosta TJ, Berisha B, Ozawa T, Sato K, Schams D and Miyamoto A: Evidence for a local endothelin-angiotensin-atrial natriuretic peptide systemin bovine mature follicles in vitro: Effects on steroid hormones and prostaglandin secretion. Biol Reprod. 61:1419–1425. 1999. View Article : Google Scholar : PubMed/NCBI
8	Stefanello JR, Barreta MH, Porciuncula PM, Arruda JN, Oliveira JF, Oliveira MA and Gonçalves PB: Effect of angiotensin II with follicle cells and insulin-like growth factor-I or insulin on bovine oocyte maturation and embryo development. Theriogenology. 66:2068–2076. 2006. View Article : Google Scholar : PubMed/NCBI
9	Nielsen AH, Hagemann A, Svenstrup B, Nielsen J and Poulsen K: Angiotensin II receptor density in bovine ovarian follicles relates to tissue renin and follicular size. Clin Exp Pharmacol Physiol. 21:463–469. 1994. View Article : Google Scholar : PubMed/NCBI
10	Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al: The androgen excess and PCOS society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril. 91:456–488. 2009. View Article : Google Scholar : PubMed/NCBI
11	Diamanti-Kandarakis E: Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 10:e32008. View Article : Google Scholar : PubMed/NCBI
12	Cho LW, Randeva HS and Atkin SL: Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag. 3:55–63. 2007.PubMed/NCBI
13	Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A and Panidis D: Polycystic ovary syndrome: The influence of environmental and genetic factors. Hormones (Athens). 5:17–34. 2006. View Article : Google Scholar : PubMed/NCBI
14	Pérez MS, Cerrone GE, Benencia H, Márquez N, De Piano E and Frechtel GD: Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome. Medicina (B Aires). 68:129–134. 2008.(In Spanish). PubMed/NCBI
15	Mlinar B, Pfeifer M, Vrtacnik-Bokal E, Jensterle M and Marc J: Decreased lipin 1 beta expression in visceral adipose tissue is associated with insulin resistance in polycystic ovary syndrome. Eur J Endocrinol. 159:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
16	Christopoulos P, Mastorakos G, Gazouli M, Panidis D, Deligeoroglou E, Katsikis I, Papadias K, Diamandi-Kandarakis E and Creatsas G: Genetic variants in TCF7L2 and KCNJ11 genes in a Greek population with polycystic ovary syndrome. Gynecol Endocrinol. 24:486–490. 2008. View Article : Google Scholar : PubMed/NCBI
17	Giacchetti G, Sechi LA, Rilli S and Carey RM: The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 16:120–126. 2005. View Article : Google Scholar : PubMed/NCBI
18	Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P and Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86:1343–1346. 1990. View Article : Google Scholar : PubMed/NCBI
19	Sun J, Fan H, Che Y, Cao Y, Wu X, Sun HX, Liang F, Yi L and Wang Y: Association between ACE gene I/D polymorphisms and hyperandrogenism in women with polycystic ovary syndrome (PCOS) and controls. BMC Med Genet. 10:642009. View Article : Google Scholar : PubMed/NCBI
20	Celik O, Yesilada E, Hascalik S, Celik N, Sahin I, Keskin L and Ozerol E: Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS. Reprod Biomed Online. 20:492–498. 2010. View Article : Google Scholar : PubMed/NCBI
21	Karabulut A, Turgut S and Turgut G: Angiotensin converting enzyme gene insertion/deletion polymorphism in patients with polycystic ovary syndrome. Gynecol Endocrinol. 26:393–398. 2010. View Article : Google Scholar : PubMed/NCBI
22	Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, . Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 27:14–24. 2012. View Article : Google Scholar : PubMed/NCBI
23	Ferriman D and Gallwey JD: Clinical Assessment of body hair growth in women. J Clin Endocrinol Metab. 21:1440–1447. 1961. View Article : Google Scholar : PubMed/NCBI
24	Amato MC, Guarnotta V, Forti D, Donatelli M, Dolcimascolo S and Giordano C: Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): A comparative analysis of four simple methods useful for metabolic assessment. Hum Reprod. 28:1919–1928. 2013. View Article : Google Scholar : PubMed/NCBI
25	Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al: Diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung and blood institute scientific statement. Circulation. 112:2735–2752. 2005. View Article : Google Scholar : PubMed/NCBI
26	Obesity, . Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 894:i-xii.1–253. 2000.
27	Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M and Galluzzo A: AlkaMeSy Study Group: Visceral adiposity index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 33:920–922. 2010. View Article : Google Scholar : PubMed/NCBI
28	Ueda S, Heeley RP, Lees KR, Elliott HL and Connell JM: Mistyping of the human angiotensin-converting enzyme gene polymorphism: Frequency, causes and possible methods to avoid errors in typing. J Mol Endocrinol. 17:27–30. 1996. View Article : Google Scholar : PubMed/NCBI
29	Apridonidze T, Essah PA, Iuorno MJ and Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 90:1929–1935. 2005. View Article : Google Scholar : PubMed/NCBI
30	Ford ES, Giles WH and Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA. 287:356–359. 2002. View Article : Google Scholar : PubMed/NCBI
31	Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN and Yang YS: Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension. 49:1442–1447. 2007. View Article : Google Scholar : PubMed/NCBI
32	Legro RS, Urbanek M, Kunselman AR, Leiby BE and Dunaif A: Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril. 78:51–57. 2002. View Article : Google Scholar : PubMed/NCBI
33	Cardoso RL, Nogueira AR, Salis LH, Urményi TP, Silva R, Moura-Neto RS, Pereira BB, Rondinelli E and Souza e Silva NA: The association of ACE gene D/I polymorphism with cardiovascular risk factors in a population from Rio de Janeiro. Braz J Med Biol Res. 41:512–518. 2008. View Article : Google Scholar : PubMed/NCBI
34	Feig JE, Hewing B, Smith JD, Hazen SL and Fisher EA: High-density lipoprotein and atherosclerosis regression: Evidence from preclinical and clinical studies. Circ Res. 114:205–213. 2014. View Article : Google Scholar : PubMed/NCBI
35	Deepika ML, Reddy KR, Rani VU, Balakrishna N, Latha KP and Jahan P: Do ACE I/D gene polymorphism serve as a predictive marker for age at onset in PCOS? J Assist Reprod Genet. 30:125–130. 2013. View Article : Google Scholar : PubMed/NCBI